altRx · Compounded semaglutide (injection)

Editorial tradeoffs

Useful for comparing: People comparing licensed-provider access to compounded semaglutide or tirzepatide with included telehealth consultations and nationwide stated availability

Limitations in the record

• One provider-wide first charge and recurring total is not established across the published treatment prices
• Reported policy: request cancellation through patient support or the patient portal if available at least 72 hours before the next billing date to stop the next charge. A request inside that window leaves that cycle's charge non-refundable and takes effect at the start of the subsequent cycle. Cancellation stops future renewal, not refunds of paid terms; multi-month and bundled plans are indivisible and non-refundable in whole or part. The provider-initiated medical-disqualification exception refunds the unused portion of the then-current term after deducting services already rendered and stops future billing. Do not state an unqualified no-refund rule. The freshly captured Terms separately say forty-eight (48) hours and incorporate additional terms; telehealth consent says no refunds or exchanges. These different source statements are preserved in typed-facts-spec.json, not silently adjudicated or turned into a refund promise.
• Provider availability and prescribing authority vary by state

Feature evidence and unknowns

Care timing is not stated.

altRx states that compounded semaglutide and compounded tirzepatide are prepared by state-regulated 503A compounding pharmacies.